Can Cipla challenge the dominance of GSK's Advair?
This article was originally published in Scrip
A generic challenge to GlaxoSmithKline's top-selling asthma drug, Advair (fluticasone plus salmeterol), may be on the way, with India's Cipla claiming that its generic product offers "identical activity" to Advair and that its delivery system could match GSK's Diskus, the intricate device through which the combination is inhaled.
You may also be interested in...
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.